Small Cap Feast

25th October 2023

Dish of the day
No Joiners today
Off the menu
No leavers today
Dish Of The Day:

Cykel AI has joined the Access Segment of the AQSE Growth Market today.

No leavers today.

What’s Cooking In The IPO Kitchen?

Announced ITF 2 October: Adsure Services, the holding company for TIAA Limited, a specialist business assurance provider operating across the Housing, Healthcare, Government, Education, Charities, and other sectors in the UK, intends to join the Access Segment of the AQSE Growth Market. Admission expected on 30 October.

MicroSalt, the developer of salt-producing technology designed to deliver full flavor with less sodium, announces the launch of an exempt public offer of shares to retail investors for up to £2.5m via PrimaryBid as part of its spin out from AIM listed Tekcapital plc (TEK.L). Microsalt announced revenues of US$0.638m in 2022, its first year of retail sales of SaltMe Crisp brand and Microsalt salt shakers in US based supermarkets and through Amazon US. Admission delayed, expected mid-November.

Breakfast Buffet

ANGLE 11.25p £29.3m (AGL.L)
The liquid biopsy Company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, announces the publication of a study using the Parsortix system that sheds new light on the phenotypic characteristics of CTCs in Head and Neck Squamous Cell Carcinoma (HNSCC). The study evaluated 41 key biomarkers including the immune checkpoint proteins PD-L1, CTLA4 and CD39 and provided key information to support the development of personalised treatment strategies in HNSCC.

Arkle Resources 0.50p £2.0m (ARK.L)
The Ireland-based exploration and resource development Company announces that it has been granted a new lithium exploration block north of its Mine River Block in Wicklow/Wexford in Ireland. The new block consists of four prospecting licences for lithium, rare earth elements and other minerals, including gold and platinum. The licences cost a total of €3,000 and Arkle is required to spend a minimum of €10,000 in exploration costs on each licence over the next 24 months. The ground is contiguous with the International Lithium Corp - Gangfeng Lithium Co. Ltd joint venture to the west, where a large zone of lithium bearing pegmatites has been discovered associated with the Leinster Granite Pegmatite Belt. The Directors believe this new ground is fertile for lithium deposits.

Creo Medical Group 34p £122.8m (CREO.L)
The medical device Company focused on the emerging field of minimally invasive surgical endoscopy announces that following a recent submission to the Company's notified body, Creo have been advised on a regulatory pathway facilitating the launch of Speedboat UltraSlim device approximately 18 months ahead of schedule. This will enable the Company to initiate the launch of UltraSlim in Europe in early 2024, with an early adopter launch programme which would otherwise have been planned for mid-2025.

Crystal Amber Fund 64p £53.3m (CRS.L)
The activist fund investing predominantly in small and mid-cap UK equities announces its final results for the year ended 30 June 2023. Adjusting for the 45p a share of dividends paid, the Net Asset Value (NAV) per share decreased by 4.6% as at 30 June 2023 to 93.33p. NAV since the year end has increased over the three months to 30 September 2023 by 6.8%. At 30 June 2023, the Fund held equity investments in six companies (2022: nine) and debt instruments in Morphic Medical Inc (formerly GI Dynamics Inc.) and Sigma Broking Limited.

IG Design Group 127.5p £125.2m (IGR.L)
The designer and manufacturer of gift packaging, craft & creative play, stationery and related product categories provides a trading update for the six months ended 30 September 2023. The Board believes the trading results for the full year to 31 March 2024 remain in line with its expectations. This represents a strong year-on-year improvement in profit and cash flow compared to the prior financial year, albeit sales will be lower for the reasons given. This demonstrates continued delivery of the Board's aspiration to return to pre-pandemic operating margins by the end of FY2025.

Molecular Energies 90p £9.3m (MEN.L)
The oil and gas exploration and production Company provides an operational update. Regarding the Paraguay Drilling, the final on-site commissioning of the drilling rig is taking place. The Company understands from the drilling company that the repaired blow out preventer (BOP) has passed its operational tests in Brazil, from where it is due to be shipped, and is currently expected to be on site at or around the end of the second week of November. The cash flow from the recent sale of the Argentine hydrocarbon assets will commence in 2024. Irrespective of the outcome of the Paraguay exploration program, the Company intends to focus on originating and developing alternative energy projects.

Orcadian Energy 21.5p £16.2m (ORCA.L)
The oil and gas development Company announces that the North Sea Transition Authority (NSTA) has confirmed that, on the basis of the work that Orcadian and the Proposed Operator intend to undertake on Seaward Production Licence P2244 (P2244), NSTA is prepared to agree an extension to the Second Term of Licence P2244. The extension would change the expiry date of the Second Term of P2244 from 30 November 2023 to 30 November 2025.

Oxford Metrics 89p £116.1m (OMG.L)
The smart sensing software Company provides a trading update for the financial year ended 30 September 2023. The Group expects to report revenues of £44.0m and an adjusted PBT of £6.3m, both ahead of current market expectations. The Group finished the year with a cash position of £64.8m and no debt. Following the Group's strongest-ever first half performance, momentum continued into the second half driven by a particularly strong contribution from the Engineering and Life Sciences segments. The Group will pursue organic growth and M&A opportunities in the year ahead.

SkinBioTherapeutics 25.5p £44.2m (SBTX.L)
The UK-based life science company focused on skin health issues a trading update. Trading for the full year to June 2023 was in line with market expectations. Cash at the year end was £1.3m and the Company continues to control its costs. Furthermore, the Company is commencing a consumer study on 300 participants in the UK about a novel acne formula. The study will be conducted in partnership with Winclove Probiotics and is expected to complete by the end of 2023, with results in Q1 2024.

Virgin Wines 39p £21.80m (VINO.L)
One of the UK's largest direct-to-consumer online wine retailers announces its audited results for the year ended 30 June 2023 (FY23). Revenue was £59.0m, down 15% (FY22: £69.2m) and in line with expectations. Adjusted EBITDA was £1.8m, down 71% (FY22: £6.2m). The net cash balance at 30 June 2023 was £5.5m (1 July 2022: £7.7m), with no debt. Sales in Q1 FY24 increased 12% year-on-year, as conversion and cancellation rates continue to improve. The Board expects double-digit sales growth in FY 2024, with an EBITDA margin of c. 4-5% as inflationary pressures start to ease.

25 October 2023
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged


Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram